US Pharma MarketingVertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.
Vertex to acquire Crinetics in $10B foray into endocrine disease drugs
Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.
Source: BioPharma Dive